Table 2. The association of PAK1, pERK and nuclear β-catenin expression with the response to cisplatin-based therapy in lung cancer patients.
| No | Tumor response |
|||
|---|---|---|---|---|
| Poor | Favorable | P | ||
| PAK1 | ||||
| Low | 46 | 17(37) | 29(63) | 0.014 |
| High | 41 | 26(63) | 15(36) | |
| pERK | ||||
| Low | 30 | 6(20) | 24(80) | <0.001 |
| High | 57 | 37(65) | 20(35) | |
| Nuclear β-catenin | ||||
| Low | 45 | 15(33) | 30(67) | 0.002 |
| High | 42 | 28(67) | 14(33) | |
Complete response (CR): a complete disappearance of all the tumors; partial response (PR): a decrease in size or number of the tumor lesions by 50% or more; progressive disease (PD): at least 25% increase in size or number of the tumor lesions; and stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Therefore, the favorable response (CR and PR) is the decrease of tumor size at least 50% or more.